Latest CD4 Stories
The drugs used to treat individuals infected with HIV-1 keep the virus under control and dramatically improve prognosis, but they do not eliminate the virus from the body completely, some remains hidden in immune cells known as resting CD4+ T cells.
RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.
A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines.
Why is the immune system able to fight off some viruses but not others, leading to chronic, life-threatening infections like HIV and hepatitis C?
A new report from the Naval Medical Center in San Diego said that CD4+ cell counts among newly-diagnosed HIV patients in the U.S. fell from 1985 to 2007, suggesting the virus may be growing more virulent.
Begin treatment as early as possible: this general common sense rule seems to apply to most diseases except HIV-AIDS, which is only treated once a certain number of immune cells called "CD4+" cells have disappeared.
The first antiretroviral treatments appeared in 1996. Since then, new and better drugs have been discovered that have almost turned AIDS into a chronic disease. Nevertheless, there is still room to improve the performance of the the therapeutic strategies used in clinical practice.
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.
Therapeutic Approach Provides HIV-Resistant Immune Cells RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.